Lion Point Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Lion Point Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$787K	Hold	36,000	–	–	3.76%	9
2026 Q1	$841K	Hold	36,000	–	–	5.03%	6
2025 Q4	$756K	Sell	36,000 -19,000	-35%	-$331K	3.91%	9
2025 Q3	$846K	Hold	55,000	–	–	4.81%	10
2025 Q2	$515K	Hold	55,000	–	–	3.5%	14
2025 Q1	$676K	Hold	55,000	–	–	4.31%	11
2024 Q4	$727K	Buy	55,000 +8,800	+19%	+$151K	3.81%	11
2024 Q3	$889K	Sell	46,200 -18,800	-29%	-$388K	1.98%	13
2024 Q2	$1.33M	Hold	65,000	–	–	2.43%	10
2024 Q1	$1.55M	Buy	65,000 +30,500	+88%	+$680K	0.86%	12
2023 Q4	$746K	Hold	34,500	–	–	0.37%	16
2023 Q3	$501K	Hold	34,500	–	–	0.22%	24
2023 Q2	$722K	Buy	+34,500	New	+$718K	0.33%	20

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Lion Point Capital's SNDX Position: Q2 2026 in Review

Lion Point Capital held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 36,000 shares worth $787K. The position accounts for 3.76% of the portfolio, ranked #9.

Lion Point Capital first reported a position in SNDX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.55M in Q1 2024. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Lion Point Capital held 36,000 shares of Syndax Pharmaceuticals worth $787K as of Q2 2026.
Lion Point Capital left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
Syndax Pharmaceuticals made up 3.76% of Lion Point Capital's portfolio in Q2 2026, its #9 holding.
Lion Point Capital first reported a position in Syndax Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Lion Point Capital's Syndax Pharmaceuticals position peaked at $1.55M in Q1 2024.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.